Please enable JavaScript to continue using this application.

Compare $CATX vs $RCKT | Chartloom

Compare

$CATX vs $RCKT

Perspective Therapeutics Inc · Rocket Pharmaceuticals Inc

CATX

Perspective Therapeutics Inc

RCKT

Rocket Pharmaceuticals Inc

Compare $CATX vs $RCKT

Comparing Perspective Therapeutics Inc and Rocket Pharmaceuticals Inc

CATXPerspective Therapeutics Inc

RCKTRocket Pharmaceuticals Inc

CATXPerspective Therapeutics Inc

Market cap

$303M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-66.9%

YTD performance

-4.7%

52W performance

-31.1%

FCF yield

-40.0%

RCKTRocket Pharmaceuticals Inc

Market cap

$280M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

34.18x

Rev growth (TTM)

—

YTD performance

-26.0%

52W performance

-24.5%

FCF yield

-61.0%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CATX

RCKT

Detailed metrics comparison

CATX

Perspective Therapeutics Inc

RCKT

Rocket Pharmaceuticals Inc

Market Cap

CATX$303M

RCKT$280M

Enterprise Value

CATX$256M

RCKT$76M

Price

CATX$2.66

RCKT$2.56

P/E Ratio

CATXN/A

RCKTN/A

P/S Ratio

CATX741.74x

RCKT0.00x

EV/Sales

CATX627.10x

RCKT0.00x

EV/EBITDA

CATX0.00x

RCKT8.60x

P/B Ratio

CATX0.97x

RCKT0.76x

P/FCF Ratio

CATXN/A

RCKTN/A

EV/FCF

CATX-2.11x

RCKT-0.45x

PEG Ratio

CATXN/A

RCKTN/A

Forward P/E (NTM)

CATXN/A

RCKTN/A

Forward P/S (NTM)

CATXN/A

RCKT34.18x

Revenue (TTM)

CATX$409K

RCKT$0

Revenue Growth (YoY)

CATX-66.9%

RCKTN/A

Forward Rev Growth

CATX32.5%

RCKT833.4%

Gross Margin (TTM)

CATX23.0%

RCKT0.0%

Operating Margin (TTM)

CATX0.0%

RCKT0.0%

EBITDA Margin (TTM)

CATX-29628.1%

RCKT0.0%

Net Margin (TTM)

CATX-28468.0%

RCKT0.0%

FCF Margin (TTM)

CATX-29657.2%

RCKTN/A

Net Income (TTM)

CATX$-116M

RCKT$-17M

FCF (TTM)

CATX$-121M

RCKT$-171M

EPS (TTM)

CATX-$0.97

RCKT-$0.15

ROE (TTM)

CATX-4156.0%

RCKT-576.0%

ROA (TTM)

CATX-3413.0%

RCKT-490.0%

ROIC (TTM)

CATX-4132.0%

RCKT-538.0%

Cash

CATX$48M

RCKT$225M

Debt

CATX$2M

RCKT$21M

Net Cash/Debt

CATX$47M

RCKT$203M

Current Ratio (TTM)

CATX6.61x

RCKT9.24x

Quick Ratio (TTM)

CATX6.49x

RCKT9.06x

Debt/Equity (TTM)

CATX0.00x

RCKT0.06x

Debt/Assets (TTM)

CATX0.0%

RCKT0.0%

Interest Coverage (TTM)

CATXN/A

RCKTN/A

Net Debt/EBITDA (TTM)

CATX0.00x

RCKT0.00x

Beta

CATX1.87

RCKT0.48

52W Performance

CATX-31.1%

RCKT-24.5%

YTD Performance

CATX-4.7%

RCKT-26.0%

% from 52W High

CATX-56.8%

RCKT-53.0%

% from 52W Low

CATX35.7%

RCKT5.8%

Asset Turnover (TTM)

CATX0.00x

RCKT0.00x

FCF Yield (TTM)

CATX-40.0%

RCKT-61.0%

Earnings Yield (TTM)

CATX-38.4%

RCKT-6.2%

Dividend Yield (TTM)

CATXN/A

RCKTN/A

Rule of 40

CATX-29,724.1

RCKT0.0

EV/GP/RG

CATX22.31

RCKTN/A

Ticker research

View CATX research View RCKT research

Metric	CATX Perspective Therapeutics Inc	RCKT Rocket Pharmaceuticals Inc
Market & Valuation
Market Cap	$303M	$280M
Enterprise Value	$256M	$76M
Price	$2.66	$2.56
P/E Ratio	N/A	N/A
P/S Ratio	741.74x	0.00x
EV/Sales	627.10x	0.00x
EV/EBITDA	0.00x	8.60x
P/B Ratio	0.97x	0.76x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.11x	-0.45x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	34.18x
Revenue & Growth
Revenue (TTM)	$409K	$0
Revenue Growth (YoY)	-66.9%	N/A
Forward Rev Growth	32.5%	833.4%
Profitability
Gross Margin (TTM)	23.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-29628.1%	0.0%
Net Margin (TTM)	-28468.0%	0.0%
FCF Margin (TTM)	-29657.2%	N/A
Net Income (TTM)	$-116M	$-17M
FCF (TTM)	$-121M	$-171M
EPS (TTM)	-$0.97	-$0.15
ROE (TTM)	-4156.0%	-576.0%
ROA (TTM)	-3413.0%	-490.0%
ROIC (TTM)	-4132.0%	-538.0%
Financial Health
Cash	$48M	$225M
Debt	$2M	$21M
Net Cash/Debt	$47M	$203M
Current Ratio (TTM)	6.61x	9.24x
Quick Ratio (TTM)	6.49x	9.06x
Debt/Equity (TTM)	0.00x	0.06x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.87	0.48
52W Performance	-31.1%	-24.5%
YTD Performance	-4.7%	-26.0%
% from 52W High	-56.8%	-53.0%
% from 52W Low	35.7%	5.8%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-40.0%	-61.0%
Earnings Yield (TTM)	-38.4%	-6.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-29,724.1	0.0
EV/GP/RG	22.31	N/A
Ticker research	View CATX research	View RCKT research

Valuation

P/S Ratio

RCKT

0.00x

CATX

741.74x

EV/FCF

CATX

-2.11x

RCKT

-0.45x

Growth & revenue

Revenue Growth TTM

CATX

-66.9%

Forward Revenue Growth

RCKT

833.4%

CATX

32.5%

Profitability & performance

Gross Margin

CATX

23.0%

RCKT

0.0%

ROE

RCKT

-576.0%

CATX

-4156.0%

FCF Yield %

CATX

-40.0%

RCKT

-61.0%

52-Week Performance

RCKT

-24.5%

CATX

-31.1%

Detailed metrics comparison

CATX

Perspective Therapeutics Inc

RCKT

Rocket Pharmaceuticals Inc

Market Cap

CATX$303M

RCKT$280M

Enterprise Value

CATX$256M

RCKT$76M

Price

CATX$2.66

RCKT$2.56

P/E Ratio

CATXN/A

RCKTN/A

P/S Ratio

CATX741.74x

RCKT0.00x

EV/Sales

CATX627.10x

RCKT0.00x

EV/EBITDA

CATX0.00x

RCKT8.60x

P/B Ratio

CATX0.97x

RCKT0.76x

P/FCF Ratio

CATXN/A

RCKTN/A

EV/FCF

CATX-2.11x

RCKT-0.45x

PEG Ratio

CATXN/A

RCKTN/A

Forward P/E (NTM)

CATXN/A

RCKTN/A

Forward P/S (NTM)

CATXN/A

RCKT34.18x

Revenue (TTM)

CATX$409K

RCKT$0

Revenue Growth (YoY)

CATX-66.9%

RCKTN/A

Forward Rev Growth

CATX32.5%

RCKT833.4%

Gross Margin (TTM)

CATX23.0%

RCKT0.0%

Operating Margin (TTM)

CATX0.0%

RCKT0.0%

EBITDA Margin (TTM)

CATX-29628.1%

RCKT0.0%

Net Margin (TTM)

CATX-28468.0%

RCKT0.0%

FCF Margin (TTM)

CATX-29657.2%

RCKTN/A

Net Income (TTM)

CATX$-116M

RCKT$-17M

FCF (TTM)

CATX$-121M

RCKT$-171M

EPS (TTM)

CATX-$0.97

RCKT-$0.15

ROE (TTM)

CATX-4156.0%

RCKT-576.0%

ROA (TTM)

CATX-3413.0%

RCKT-490.0%

ROIC (TTM)

CATX-4132.0%

RCKT-538.0%

Cash

CATX$48M

RCKT$225M

Debt

CATX$2M

RCKT$21M

Net Cash/Debt

CATX$47M

RCKT$203M

Current Ratio (TTM)

CATX6.61x

RCKT9.24x

Quick Ratio (TTM)

CATX6.49x

RCKT9.06x

Debt/Equity (TTM)

CATX0.00x

RCKT0.06x

Debt/Assets (TTM)

CATX0.0%

RCKT0.0%

Interest Coverage (TTM)

CATXN/A

RCKTN/A

Net Debt/EBITDA (TTM)

CATX0.00x

RCKT0.00x

Beta

CATX1.87

RCKT0.48

52W Performance

CATX-31.1%

RCKT-24.5%

YTD Performance

CATX-4.7%

RCKT-26.0%

% from 52W High

CATX-56.8%

RCKT-53.0%

% from 52W Low

CATX35.7%

RCKT5.8%

Asset Turnover (TTM)

CATX0.00x

RCKT0.00x

FCF Yield (TTM)

CATX-40.0%

RCKT-61.0%

Earnings Yield (TTM)

CATX-38.4%

RCKT-6.2%

Dividend Yield (TTM)

CATXN/A

RCKTN/A

Rule of 40

CATX-29,724.1

RCKT0.0

EV/GP/RG

CATX22.31

RCKTN/A

Ticker research

View CATX research View RCKT research

Metric	CATX Perspective Therapeutics Inc	RCKT Rocket Pharmaceuticals Inc
Market & Valuation
Market Cap	$303M	$280M
Enterprise Value	$256M	$76M
Price	$2.66	$2.56
P/E Ratio	N/A	N/A
P/S Ratio	741.74x	0.00x
EV/Sales	627.10x	0.00x
EV/EBITDA	0.00x	8.60x
P/B Ratio	0.97x	0.76x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.11x	-0.45x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	34.18x
Revenue & Growth
Revenue (TTM)	$409K	$0
Revenue Growth (YoY)	-66.9%	N/A
Forward Rev Growth	32.5%	833.4%
Profitability
Gross Margin (TTM)	23.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-29628.1%	0.0%
Net Margin (TTM)	-28468.0%	0.0%
FCF Margin (TTM)	-29657.2%	N/A
Net Income (TTM)	$-116M	$-17M
FCF (TTM)	$-121M	$-171M
EPS (TTM)	-$0.97	-$0.15
ROE (TTM)	-4156.0%	-576.0%
ROA (TTM)	-3413.0%	-490.0%
ROIC (TTM)	-4132.0%	-538.0%
Financial Health
Cash	$48M	$225M
Debt	$2M	$21M
Net Cash/Debt	$47M	$203M
Current Ratio (TTM)	6.61x	9.24x
Quick Ratio (TTM)	6.49x	9.06x
Debt/Equity (TTM)	0.00x	0.06x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.87	0.48
52W Performance	-31.1%	-24.5%
YTD Performance	-4.7%	-26.0%
% from 52W High	-56.8%	-53.0%
% from 52W Low	35.7%	5.8%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-40.0%	-61.0%
Earnings Yield (TTM)	-38.4%	-6.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-29,724.1	0.0
EV/GP/RG	22.31	N/A
Ticker research	View CATX research	View RCKT research